Cambridge, USA-based CAMP4 Therapeutics has entered into a strategic research, collaboration and license agreement with UK ...
An Expert View piece looking forward to next year from the global strategy consultancy's Simon Middleton, head, Europe Life ...
California, USA-based Vistagen yesterday announced that the PALISADE-3 Phase III study of intranasal fasedienol for the acute ...
RNAi therapeutics company Alnylam Pharmaceuticals has announced the planned expansion of its manufacturing facility in Norton ...
US pharma major Eli Lilly (NYSE: LLY) has reported positive topline data from its Phase III ATTAIN-MAINTAIN trial, showing that its oral GLP-1 candidate orforglipron helped patients maintain weight ...
US pharma Viatris (Nasdaq: VTRS) has logged four regulatory milestones across its global pipeline, spanning a US Food and ...
A clinical-stage biotechnology company headquartered in Schlieren (Zurich), Switzerland. The company develops locally acting ...
US healthcare giant Johnson & Johnson announced that the US Food and Drug Administration (FDA) approved Rybrevant Fasbro ...
US biotech Cytokinetics (Nasdaq: CYTK) has secured the first global approval for its cardiac myosin inhibitor aficamten, ...
US biotech VYNE Therapeutics has agreed to merge with privately held Yarrow Bioscience in an all-stock transaction, pivoting ...
US biopharma Insmed Incorporated has announced that the Phase IIb BiRCh study of brensocatib in chronic rhinosinusitis ...
Japanese drugmaker Takeda has announced positive topline results for two pivotal Phase III studies of zasocitinib (TAK-279), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results